Stockscreener 앱 받기
43.83
0.00%
0.00
시간 외 거래:
43.78
-0.05
-0.11%
Bristol Myers Squibb Co 주식(BMY)의 최신 뉴스
Why Bristol Myers Squibb Company Equity Right stock is popular among millennialsRecession Risk & Verified High Yield Trade Plans - newser.com
How high can Bristol Myers Squibb Company stock goEarnings Recap Summary & Consistent Return Investment Signals - newser.com
Visualizing Bristol Myers Squibb Company stock with heatmaps2025 Earnings Surprises & Daily Entry Point Trade Alerts - newser.com
Bristol Myers (BMY) Reports Promising Results from Phase 1 Study in Autoimmune Diseases - GuruFocus
Will Bristol Myers Squibb Company (BRM) stock beat growth indexesNew Guidance & Free Expert Approved Momentum Trade Ideas - newser.com
How Bristol Myers Squibb Company Celegne Contingent stock trades under stagflationJuly 2025 Catalysts & Fast Exit Strategy with Risk Control - newser.com
Bristol Myers Squibb reports positive early results from CAR T therapy trial - Investing.com
Bristol Myers Squibb (NYSE: BMY) shares Phase 1 CD19 CAR T in 71 autoimmune patients - Stock Titan
BRISTOL-MYERS SQUIBB CO USD2 CNV CUM PFD USD1 (BMYMP.US) is scheduled to release its earnings report before the market opens on October 30. - 富途牛牛
Applying chart zones and confluence areas to Bristol Myers Squibb CompanyJuly 2025 Highlights & Safe Swing Trade Setup Alerts - newser.com
PFE versus BMY: Which Large Oncology Drugmaker Is a Better Pick Now? - The Globe and Mail
Is Bristol Myers Squibb Company stock resilient to inflationPortfolio Growth Summary & Accurate Entry and Exit Point Alerts - newser.com
Analyst Says Bristol-Myers Squibb (BMY) Among the Best ‘Deep Value’ Stocks to Buy - Yahoo Finance
Risk adjusted return profile for Bristol Myers Squibb Company Equity Right analyzedPortfolio Profit Report & AI Enhanced Trading Alerts - newser.com
Forecasting Bristol Myers Squibb Company Equity Right price range with options dataMarket Volume Summary & Fast Exit/Entry Strategy Plans - newser.com
Will Bristol Myers Squibb Company stock deliver better than expected guidanceTrade Risk Summary & Low Drawdown Trading Strategies - newser.com
Can Bristol-Myers Squibb’s Innovation Push Reverse Its Stock Slide? - AD HOC NEWS
Is Bristol Myers Squibb Company (BRM) stock cheap vs fundamentalsJuly 2025 Selloffs & AI Forecast for Swing Trade Picks - newser.com
Bristol-Myers $450M Payment Dispute Heads To Arbitration - Law360
Checking In on The Trade Desk, Bristol Myers Squibb, and Other Stocks - The Motley Fool
Bristol Myers Squibb (BMY) Stock Moves 2.18%: What You Should Know - Yahoo Finance
Trend analysis for Bristol Myers Squibb Company this week2025 Technical Overview & Stepwise Trade Signal Implementation - newser.com
The Play On Bristol-Myers Squibb (NYSE:BMY) - Seeking Alpha
Citi Raises PT on Bristol-Myers Squibb Company (BMY) Stock - Insider Monkey
Small Cell Lung Cancer Market Research 2025-2035: Growth Driven by Advancements in Novel Therapies, Including Immunotherapies, Targeted Therapies, and Combination Treatments - GlobeNewswire Inc.
Will Bristol Myers Squibb Company Celegne Contingent stock benefit from Fed rate cuts2025 Technical Overview & High Accuracy Swing Entry Alerts - newser.com
Bristol-Myers’ $450 Million Earnout Pay Fight Sent to Arbitrator - Bloomberg Law News
US CBO says orphan drug exemption could add $6 billion to cost of Trump's 'Big Beautiful Bill' - Reuters
Can Bristol-Myers Squibb Stock Recover After Steep Decline? - AD HOC NEWS
Bristol-Myers Squibb (BMY) Investor Outlook: Navigating a 21.59% Potential Upside Amidst Strong Dividend Yield - DirectorsTalk Interviews
Can Bristol Myers Squibb Company stock hit record highs againMarket Performance Recap & Expert Verified Movement Alerts - newser.com
Bristol Myers (BMY) Reports Positive Trial Data on Cancer Drug - GuruFocus
Bristol Myers Squibb (BMY) Reports Promising Phase I Trial Resul - GuruFocus
Bristol Myers Squibb, SystImmune report data from lung cancer trial - Seeking Alpha
SystImmune, Inc. and Bristol Myers Squibb Announce First Global Phase I Results of Iza-bren, an EGFR x HER3 Bispecific Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors at ESMO 2025 - Yahoo Finance
Bristol Myers Squibb Foundation Awards Grant to PATH to Improve Care for Inherited Blood Disorders in India - Yahoo Finance
Is Bristol Myers Squibb Company Equity Right building a consolidation baseMarket Trend Review & Step-by-Step Trade Execution Guides - newser.com
Does Bristol Myers Stock Offer Value as AI Data-Sharing Alliance Makes Headlines? - simplywall.st
insitro and Bristol Myers Squibb (BMY) Advance ALS Research with New AI-Powered Collaboration - Yahoo Finance
Bristol Myers Squibb Launches Kopozgo (Mavacamten) In IndiaStatement - TradingView
What machine learning models say about Bristol Myers Squibb CompanyWatch List & Fast Moving Stock Trade Plans - newser.com
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
Bristol-Myers Squibb (BMY) Expands Cell Therapy Portfolio with $1.5 Billion Orbital Therapeutics Deal - Insider Monkey
insitro Extends Research Collaboration with Bristol Myers Squibb Leveraging insitro’s ChemML Discovery Platform - BioSpace
insitro, Bristol Myers Squibb extend ALS collaboration with AI focus - Investing.com
insitro, Bristol Myers Squibb extend ALS collaboration with AI focus By Investing.com - Investing.com Australia
BMY Collaboration Advances ALS Treatment Development - GuruFocus
$20M Added to insitro–Bristol Myers Squibb ALS Collaboration; Novel ALS Target Identified - Stock Titan
Bristol Myers Squibb describes new FAK degradation inducers - BioWorld MedTech
11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients with Toy-Making Workshops Across the Region - PR Newswire UK
Bristol Myers Squibb acquires cell therapy biotech Orbital for $1.5bn - European Pharmaceutical Review
What Bristol-Myers Squibb (BMY)'s FDA Fast Track for Alzheimer’s Drug Means for Shareholders - simplywall.st
Bristol Myers' $1.5 Billion RNA Gamble: Could Orbital Therapeutics Rewire Its Future? - Smartkarma
What to Expect From Bristol-Myers Squibb's Next Quarterly Earnings Report - inkl
Analyzing net buyer seller activity in Bristol Myers Squibb Company Equity RightWeekly Investment Recap & Smart Investment Allocation Tips - newser.com
Bristol-Myers Squibb (BMY): Strong Growth Pipeline Supports High-Yield Dividend - Insider Monkey
Why Top Investors Are Buying Bristol-Myers Squibb Co (BMY) - The Acquirer's Multiple
Pharma companies announce direct-to-consumer sales and price cuts in US - Reuters
Bristol Myers Faces Legacy Headwinds But Banks On Its Pipeline - Finimize
4.28%
0.39%
자본화:
|
볼륨(24시간):